Illumina Company Description

Illumina, Inc. offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally.

It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.

It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services; and Galleri, a multi-cancer early detection test.

In addition, the company is developing solutions to help accelerate cancer diagnoses, blood-based detection for minimal residual disease, and other post-diagnostic applications.

The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies.

It markets and distributes its products directly to customers, as well as through life-science distributors.

Illumina, Inc. was incorporated in 1998 and is based in San Diego, California.

Illumina, Inc.

Country	United States
Founded	1998
Industry	Diagnostics & Research
Sector	Healthcare
Employees	10,640
CEO	Jacob Thaysen

Contact Details

Address: 5200 Illumina Way San Diego, Delaware 92122 United States
Phone	858 202 4500
Website	illumina.com

Stock Details

Ticker Symbol	ILU
Exchange	Deutsche Börse Xetra
Fiscal Year	January - December
Reporting Currency	USD
ISIN Number	US4523271090
SIC Code	3826

Key Executives

Name	Position
Jacob Thaysen	Chief Executive Officer
Kevin Pegels	Chief Operating Officer
Sallilyn Schwartz	Head of Investor Relations